PMS2 and Lynch syndrome: Collectively, these are referred to as path_MMR variants.1 Lynch syndrome “carriers” carry a path_MMR variant but may never develop cancer, especially with path_PMS2 or path_MSH6 variants, which confer lower risks (Holter et al., 2022).